Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This approval was based on a study that showed an overall response rate of 75% and complete remission...

ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) continues to be the standard of care for patients with advanced-stage Hodgkin lymphoma (HL). Consolidation of primary chemotherapy with radiation or autologous stem cell transplantation (ASCT) has not demonstrated an improvement in overall survival in randomized controlled trials. Regimens such as escalated BEACOPP have more acute and l...

Hodgkin's lymphoma accounts for ten percent of all lymphomas. In the United States, there are about 8000 new cases every year. This paper describes a case of lymphocyte-rich Hodgkin's lymphoma (LRHL) manifested by autoimmune hemolytic anemia (AIHA). A 27-year-old Israeli male presented with dizziness associated with one month of low-grade fevers and night sweats; he also complained of persisten...

Introduction: Inhibitors of programmed cell death receptor 1 (PD1) used with chemotherapy result in high response rates and durable remissions the first line (1L) treatment classical Hodgkin Lymphoma (cHL). Avelumab is an inhibitor immune checkpoint PDL1, which highly expressed by Reed-Sternberg cells, has demonstrated activity relapsed/refractory cHL. The AVENuE window study assessed efficacy ...

Although eosinophilia is a recognised associated feature of Hodgkin’s Lymphoma, hypereosinophilia seldom the presenting in patient. Here, authors report an unusual case 21-year-old male patient who presented to General Medicine outpatient department hospital with history multiple episodes left-sided pleural effusion addition mediastinal and cervical lymphadenopathy. Baseline investigations reve...

Background. Hemophagocytic syndrome (HPS) is characterized by a hyperinflammatory reaction followed by alteration in cytotoxic function of Th1 lymphocytes and natural killer cells. We report a rare case of a patient that presented with fever and pancytopenia due to HPS associated with Hodgkin's lymphoma (HL). Case Report. A 69-year-old Caucasian woman was admitted presenting with complaints of ...

The patient was a 32-year-old woman diagnosed 18 months earlier with nodular sclerosing Hodgkin lymphoma, Ann Arbor stage IIIA (supradiaphragmatic and infradiaphragmatic lymph node involvement and absence of B symptoms). She had initially been treated with 6 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine). On recurrence of the lymphoma, she was treated with 2 cycles of c-MO...

Introduction: Interim PET is highly predictive of outcome for patients (pts) with stage III or IV Hodgkin lymphoma (HL) treated 6 cycles Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD). The RATHL study showed that PET-2 negative (neg) pts receiving ABVD can stop bleomycin after 2 without compromising efficacy. Furthermore, positive (pos) appear to have improved outcomes if treatment inte...